MIRA
INFORM REPORT
|
Report Date : |
05.05.2012 |
IDENTIFICATION DETAILS
|
Name : |
hebei
union pharmaceutical cO., lTD. |
|
|
|
|
Registered Office : |
No. 58, |
|
|
|
|
Country : |
|
|
|
|
|
Date of Incorporation : |
02.04.2002 |
|
|
|
|
Com. Reg. No.: |
130000400001766 |
|
|
|
|
Legal Form : |
Wholly Foreign-Owned |
|
|
|
|
Line of Business : |
Engaged
in manufacturing & selling API and antibiotic. |
|
|
|
|
No. of Employees : |
1,000 (Including Branches) |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
Payment Behaviour : |
No complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30, 2011
|
Country Name |
Previous Rating (31.12.2011) |
Current Rating (31.03.2012) |
|
China |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Company name and address
hebei union pharmaceutical cO.,
lTD.
no. 58, cangfeng road, shijiazhuang,
hebei province, 050021 PR CHINA
TEL: 86 (0) 311-86137390
FAX: 86 (0) 311- 86137382
EXECUTIVE SUMMARY
INCORPORATION DATE :
APRIL 2, 2002
REGISTRATION NO. :
130000400001766
REGISTERED LEGAL FORM : WHOLLY FOREIGN-OWNED ENTERPRISE
STAFF STRENGTH : 1,000 (INCLUDING BRANCHES)
REGISTERED CAPITAL : CNY 22,932,000
BUSINESS LINE :
MANUFACTURING & TRADING
TURNOVER : N/A
EQUITIES : N/A
PAYMENT :
AVERAGE
MARKET CONDITION :
AVERAGE
FINANCIAL CONDITION : N/A
OPERATIONAL TREND : STEADY
GENERAL REPUTATION :
AVERAGE
EXCHANGE RATE :
CNY 6.2854 = USD
Adopted
abbreviations:
ANS - amount not
stated
NS - not stated
SC - subject
company (the company inquired by you)
NA - not available
CNY - China Yuan Renminbi
SC was registered as a wholly foreign-owned enterprise at local
Administration for industry & commerce (AIC - the official body of issuing
and renewing business license) on April 2, 2002.
Company Status: Wholly foreign-owned
enterprise This form of business in PR
China is defined as a legal person. It is a limited co. established within
the territories of PR China with capital provided totally by the foreign
investors. More than one foreign investor may jointly invest in a wholly
foreign-owned enterprise. The investing party/parties solely exercise
management, reap profit and bear risks and liabilities by themselves. This
form of companies usually have a limited duration is extendible upon approval
of Examination and Approval Authorities.
SC’s registered business scope includes manufacturing ampicillin sodium,
piperacillin sodium, azlocillin sodium, mezlocillin sodium, sulbactam sodium,
API (The production of Arbidol is limited to branches), small volume
injections; selling self-made products.
SC is
mainly engaged in manufacturing & selling API and antibiotic.
Mr. Li Peifu is
legal representative and chairman of SC at present.
SC is known to
have approx. 1,000 (including branches) employees at present.
SC
is currently operating at the above stated address, and this address houses its
operating office and factory in the industrial zone of Shijiazhuang. SC’s
employee refused to release the detailed information of the premise.
http://www.hblhzy.net The design is professional and the content is well
organized. At present it is in both Chinese and English versions.
Email: zspc_hr@163.com ; unionpharm@126.com
SC has passed ISO 9001 and GMP, SC also rated A-level enterprises in the
first tax credit ratings by ijiazhuang City in 2004; and SC’s products meet the
standards of BP, USP, CP.
No significant changes were found during our checks with the local AIC.
MAIN SHAREHOLDERS:
Name %
of Shareholding
Langli Co., Ltd. (in Chinese pinyin) 100
Note: The nationality of SC’s
shareholder is not available in local AIC.
l
Legal Representative and Chairman:
Mr. Li Peifu is currently responsible for the
overall management of SC.
Working Experience(s):
At present Working in SC as legal representative and chairman.
l
General Manager:
Mr. Jiao Ruiheng is currently responsible for
the daily management of SC.
Working Experience(s):
At present Working
in SC as general manager
l
Director:
Sun Xuwen
l
Supervisor:
Yang Mengjun
SC is
mainly engaged in manufacturing & selling API and antibiotic.
SC’s products mainly include: bulk material
and preparations
Raw
material: Ampicillin Sodium, Piperacillin Sodium, Mezlociline Sodium, Azlocillin
Sodium, Ticarcillin Sodium Sulbactam Sodium, Cefoperazone Sodium, etc.
Preparation:
Mike
Pillsbury have (salmon calcitonin injection)
Enerxin (Arbidol hydrochloride
capsules)
Bangxinshu (ibutilide fumarate injection)
SC sources its materials 95% from domestic
market, and 5% from overseas market. SC sells 50% of its products in domestic
market, and 50% to overseas market.
The buying terms of SC include Check, L/C, T/T and Credit of
30-60 days. The payment terms of SC include Check, L/C, T/T and Credit of 30-60
days.
Note:
SC’s management refused to release its main clients and suppliers.
The information on SC’s subsidiaries is not available at present.
Overall payment appraisal:
( ) Excellent (
) Good (X) Average (
) Fair ( ) Poor
( ) Not yet determined
The appraisal serves as a reference to reveal SC's payments habits and ability
to pay. It is based on the 3 weighed factors: Trade payment experience (through
current enquiry with SC's suppliers), our delinquent payment and our debt
collection record concerning SC.
Trade payment experience: SC did not
provide any name of trade/service suppliers and we have no other sources to
conduct the enquiry at present.
Delinquent
payment record: None in our database.
Debt collection record: No overdue amount owed by SC was placed to us for
collection within the last 6 years.
SC’s management
declined to release its bank details.
SC’s financial
reports were not found during our checks with the local Administration for
Industry and Commerce.
SC’s management declined
to release any financial information.
SC is considered medium-sized in its line with 10 years operation
history. Taking into consideration of SC’s general performance, reputation as
well as market conditions, credit up to moderate amount may be considered.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.53.72 |
|
|
1 |
Rs.86.98 |
|
Euro |
1 |
Rs.70.64 |
INFORMATION DETAILS
|
Report Prepared
by : |
PDT |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.